Peptech patent approved
Tuesday, 15 July, 2003
Peptech's application for a patent on antibodies or antibody fragments that bind to a specific tumour necrosis factor (TNF) has been given the green light by US patent authorities.
Managing director Mr Stephen Kwik noted that the new patent enhanced the company's already considerable anti-TNF patent portfolio, and offered the potential for further coverage under the current description.
"As the peptide represents a portion of the TNF molecule, anti-TNF antibodies that bind the peptide could fall under the scope of the patent," Kwik said.
Peptech has already licensed its technology in the fields of antibody therapeutics for inflammatory diseases such as rheumatoid arthritis, psoriasis and Crohn's disease.
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
Existing medicines could help treat deadly childhood dementia
Australian researchers have identified several existing TGA‑approved medicines that could help...
